会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • USE OF CAROTENOIDS AND/OR CAROTENOID DERIVATIVES/ANALOGS FOR REDUCTION/INHIBITION OF CERTAIN NEGATIVE EFFECTS OF COX INHIBITORS
    • 用于减少/抑制COX抑制剂某些负面影响的CAROTENOIDS和/或CAROTENOID衍生物/模拟物
    • WO2006119168A2
    • 2006-11-09
    • PCT/US2006016590
    • 2006-05-02
    • HAWAII BIOTECH INCLOCKWOOD SAMUEL FMASON R PRESTON
    • LOCKWOOD SAMUEL FMASON R PRESTON
    • A61K31/415A61K31/015A61K31/196A61K31/522A61K45/06A61K2300/00
    • Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.
    • 将类胡萝卜素,特别是叶黄素类胡萝卜素或虾青素,叶黄素,玉米黄质,lycoxanthin,番茄红素或番茄红素的类似物或衍生物施用于用COX-2抑制剂药物治疗的受试者可以减少至少一部分与 给予COX-2选择性抑制药物。 类胡萝卜素或其类似物或衍生物可以在COX-2选择性抑制剂药物治疗开始之前,同时或之后施用于受试者。 类胡萝卜素或其类似物或衍生物可以与COX-2选择性抑制剂药物治疗同时给予受试者。 类胡萝卜素或其类似物或衍生物可以与COX-2选择性抑制剂药物组合引入药物制剂中,或者可以分开施用。 本文所述的类似物或衍生物的施用可以减少经历COX-2选择性抑制剂药物治疗的受试者的血清和浆细胞膜中LDL和其它脂质的过氧化。 本文所述的类似物或衍生物的给药可以降低经历COX-2选择性抑制剂药物治疗的有害临床心血管事件的发生率。